Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$16.76
>-$0.01(-0.22%)
At close: 4:00 PM EST
$16.76
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$3.03 - $20.79
Previous CloseN/A
Volume391.09K
Average Volume (3M)3.95M
Market Cap
$4.34B
Enterprise Value$1.18K
Total Cash (Recent Filing)$642.07M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 06, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding217,940,340
10 Day Avg. Volume3,154,361
30 Day Avg. Volume3,946,958
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.45Price Target Upside45.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$11.78M
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformRelay’s unique computational/structure-based platform focused on protein motion and dynamics is a durable competitive asset. It can increase hit quality, shorten optimization cycles, and create differentiated candidates across oncology and genetic disease, supporting sustained pipeline productivity and partner interest.
Promising Clinical Data For ZovegalisibRobust Phase 2 signals in PIK3CA-driven vascular anomalies with high response rates and tolerable dosing are a structural positive: they validate mechanism, enable broader development (adult, adolescent, pediatric cohorts) and create a pathway to diversify revenues beyond oncology if later-stage trials confirm benefit.
Solid Near-term Funding Via Equity RaiseThe sizable $~297M underwritten raise materially extends runway for clinical programs and planned Phase 3 work. Reliable access to capital reduces near-term liquidity risk and underpins execution of multi-year R&D plans, an important structural enabler for clinical-stage biotech.
Bears Say
High Cash BurnSustained ~-$213M TTM cash burn is a structural constraint: it forces continued reliance on external financing, increases dilution risk, and creates execution pressure to advance programs or secure deals to avoid capital shortfalls over the next 2–6 months and beyond.
Limited And Volatile RevenueRevenue is small, variable and derived from collaborations rather than products, making cash flow timing unpredictable. Without commercial products, durable margin expansion and self-sustaining cash generation remain unlikely until successful late‑stage readouts or partner commercialization occur.
Dilution And Authorized Share IncreaseThe charter amendment and recent equity issuance materially increase dilution capacity and reflect recurring financing needs. Over time this can erode existing shareholders’ stakes and signal that further capital raises may be necessary to fund clinical development and commercialization plans.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics Inc’s price range in the past 12 months?
Relay Therapeutics Inc lowest stock price was $3.02 and its highest was $20.79 in the past 12 months.
What is Relay Therapeutics Inc’s market cap?
Relay Therapeutics Inc’s market cap is $4.34B.
When is Relay Therapeutics Inc’s upcoming earnings report date?
Relay Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Relay Therapeutics Inc’s earnings last quarter?
Relay Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.363 by -$0.047.
Is Relay Therapeutics Inc overvalued?
According to Wall Street analysts Relay Therapeutics Inc’s price is currently Undervalued.
Does Relay Therapeutics Inc pay dividends?
Relay Therapeutics Inc does not currently pay dividends.
What is Relay Therapeutics Inc’s EPS estimate?
Relay Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Relay Therapeutics Inc have?
Relay Therapeutics Inc has 217,940,340 shares outstanding.
What happened to Relay Therapeutics Inc’s price movement after its last earnings report?
Relay Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.363. Following the earnings report the stock price went down -0.615%.
Which hedge fund is a major shareholder of Relay Therapeutics Inc?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.45 (45.91% Upside)
$24.45 (45.91% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 31.9%
Last 30 Days ▲ 31.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
445.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.48%
Trailing 12-Months
Company Description
Relay Therapeutics Inc
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$24.45
▲(45.91% Upside)
Technical Analysis
Ownership Overview
1.82% Insiders
11.28% Mutual Funds
0.46% Other Institutional Investors
72.10% Public Companies and
Individual Investors